The explosive growth in biological, pharmaceutical, and human health screening technologies has challenged the analytical sciences to create methodologies for high-sample throughput. Of the many possible methodologies, capillary electrophoresis (CE) has an unrecognized potential to serve as a platform for a highly multiplexed analysis system that allows for extremely high sample throughput. However, CE traditionally suffers from unacceptably high sample-to-sample and capillary-to-capillary variations in elution profiles and injection volumes. This variability is one of the main impediments to the use of CE in routine analysis. Furthermore, today's multiplexed CE systems are based only on fluorescence read-out concepts, which are ineffective in detecting -90 percent of the likely target compounds. This project describes the design fabrication, and implementation of a 96-capillary array CE system that 1) employs an absorbance-based read-out methodology and 2) utilizes the near-continuous measurement, collection, and application of the current flow at each individual capillary. The former significantly expands the scope of the system. The latter uses the collected current for self-normalization of the electropherogram through application of the migration index, which can yield precisions that compare favorably with that of high performance liquid chromatography. Success in Phase I will lead to a Phase II program focused on optimizing the system and methods to test biological fluids to perform disease diagnosis and/or prognosis as well as combinatorial drug synthesis and activity screening. Phase II would accumulate in actual field tests being performed and compared to traditional, accepted methods.

Proposed Commercial Applications

The ultimate goal of the project for commercial applications is the creation of a packaged system that has proven capabilities for solving problems in the health-related applications (e.g., cancer gene detection, multation analysis, forensic genotyping and drug efficacy) and other areas demanding reliable, high throughput analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA090090-01A1
Application #
6404464
Study Section
Special Emphasis Panel (ZRG1-SSS-2 (10))
Program Officer
Swain, Amy L
Project Start
2001-09-15
Project End
2002-09-14
Budget Start
2001-09-15
Budget End
2002-09-14
Support Year
1
Fiscal Year
2001
Total Cost
$99,420
Indirect Cost
Name
Combisep, Inc.
Department
Type
DUNS #
City
Ames
State
IA
Country
United States
Zip Code
50011
Grossmann, A H; Kolibaba, K S; Willis, S G et al. (2004) Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl. FEBS Lett 577:555-62